Cordis buys new blood clot capture technology:
This article was originally published in Clinica
Cordis has acquired AngioGuard, a Minneapolis, Minnesota-based developer of embolic containment systems, for an undisclosed amount. The system is designed to prevent a possible stroke by capturing blood clots which become dislodged during interventional procedures such as carotid stenting and saphenous vein graft stenting. It is approved for coronary applications in Europe and Cordis expects to receive approval later this year for carotid applications. The Warren, New Jersey-based company hopes to combine its carotid stents, which are currently undergoing US clinical trials, with the newly-acquired technology.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.